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Abstract
Although microbes have been classically viewed as pathogens, it is now well established that the
majority of host-bacterial interactions are symbiotic. During development and into adulthood, gut
bacteria shape the tissues, cells and molecular profile of our gastrointestinal immune system. This
partnership, forged over many millennia of co-evolution, is based on a molecular exchange
involving bacterial signals that are recognized by host receptors to mediate beneficial outcomes
for both microbe and man. We explore herein how specific aspects of the adaptive immune system
are influenced by intestinal commensal bacteria. Understanding the molecular mechanisms which
mediate symbiosis between commensal bacteria and humans may redefine how we view the
evolution of adaptive immunity, and as a result, the way we approach treating numerous
immunologic disorders.
We are (fortunately) not alone- humans provide residence to numerous microbial
communities comprised of hundreds of individual bacterial species. Although teleological
design may predict that the immune system evolved to eliminate infectious microbes, we
now know that almost every environmentally exposed surface of our bodies is teeming with
symbiotic microbes (Fig. 1). These polymicrobial communities contribute profoundly to the
architecture and function of the tissues they inhabit, and thus play an important role in the
balance between health and disease. The notion that commensal microbes critically affect
tissue and cell development in humans can be rationalized when this process is viewed from
an evolutionary perspective. Bacteria populated the Earth 2 billion years before the first
signs of eukaryotic life, and occupy almost every terrestrial and aquatic niche on our planet.
Mitochondria and chloroplasts of eukaryotic cells are descended from bacteria, suggesting
that bacteria may have had an active role in the evolution of higher organisms. As
multicellular metazoans evolved more complex body plans, bacteria acquired the ability to
inhabit new anatomical niches. Animals represent a stable, nutrient rich ecosystem for
microbes to thrive; hence host health is paramount to the microbiota. In turn, the host
benefits from a diverse commensal microbiota which help digest complex carbohydrates and
provide essential nutrients to mammals. Symbionts are not the only microbes the host
encounters, however. An important challenge faced by the host immune system is
distinguishing between beneficial and pathogenic microbes, because both share similar
molecular patterns that are recognized by the innate immune system (such as
lipopolysaccharide, peptidogycan, lipoproteins, flagellin). Discrimination between specific
microbes may be a feature of the adaptive immune system, which can recognize discrete
molecular sequences and mount both pro- and anti-inflammatory responses depending on
the nature of the antigen. In particular, CD4+ T cells are quite plastic and differentiate into
numerous subsets after development in the thymus, and thus are capable of sensing
environmental cues from the microbiota. As adaptive immunity evolved in higher
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vertebrates, the ability of this system to recognize and respond to specific microorganisms
may have been driven by evolutionary forces provided by the microbiota itself, resulting in
immune functions beyond simply clearing microbial pathogens (which in theory also helps
the microbiota by improving host health). Recent evidence shows that the commensal
microbiota ‘programs’ many aspects of T cell differentiation, thus augmenting the
developmental instructions of the host genome to engender the full function of the adaptive
immune system.
This article will review concepts derived from gnotobiology (Greek for ‘known life’;
‘gnosis’ meaning knowledge and ‘bios’ meaning life) to unravel how commensal bacteria
promote the development and function of adaptive immunity. In particular, we will explore
how CD4+ T-helper cell subsets within the gastrointestinal and systemic immune system are
shaped (perhaps even controlled) by our microbiota, and theorize how and why gut bacteria
evolved to so profoundly influence immunologic wellbeing. Understanding human co-
evolution with our microbiota may lead to a philosophical and conceptual redefinition of the
microbial world, and provide clinical advances toward the treatment of autoimmunity and
inflammatory diseases by harnessing the immunomodulatory properties of human
commensal bacteria.
How Does the Microbiota Shape Host Immune Development and Function?
Although microbes reside in several anatomical locations including the skin, vagina and
mouth, the lower gastrointestinal tract of mammals harbors the greatest density and diversity
of commensal microorganisms. These include bacteria, archaea, fungi, viruses, protozoans
and in some cases, multicellular helminthes; however, bacteria predominate and reach 100
trillion microbial cells in the colon. Recent efforts to sequence the bacterial genomes of the
microbiota (known as the microbiome), have begun to reveal its genetic identity (1) and
suggest our microbiome contains over 150 times the number of non-redundant genes than in
the human genome (2). For decades, microbiological techniques to culture bacteria in the
laboratory have only identified cultivatable organisms, which represent a minority of the
microbial species of the gut. The aggregate human microbiota likely contains between
1,000–1,150 bacterial species (spread among all people sampled), with each person
harboring approximately 160 bacterial species (2). This suggests an individual’s microbiome
is relatively distinct in composition and adaptable to environmental changes and/or host
genetics.
Germ-free animals (born and raised in the absence of all microbes) provide important
insights into how the microbiota affects the host immune system. The development of gut-
associated lymphoid tissues (GALT), the first line of defense for the intestinal mucosa, is
defective in germ-free mice. Germ-free mice display fewer and smaller Peyer’s patches,
smaller and less cellular mesenteric lymph nodes (MLNs) and less cellular lamina propria of
the small intestine compared to animals with a microbiota (3–7). Besides developmental
defects in tissue formation, the cellular and molecular profile of the intestinal immune
system is also compromised in germ-free mice. In germ-free mice, intestinal epithelial cells
(IECs), which line the gut and form a physical barrier between luminal contents and the
immune system, exhibit reduced expression of toll-like receptors (TLRs) and major
histocompatibility molecule II (MHC II) (8–9), which are involved in pathogen sensing and
antigen presentation, respectively. Interspersed between epithelial cells is a specialized
population of T cells known as intra-epithelial lymphocytes (IELs). IELs from germ-free
mice are reduced in number, and their cytotoxicity is compromised (10–11). Microbial
colonization expands specific subsets of intestinal γδ T cells (12). Germ-free mice also have
reduced numbers of CD4+ T cells in the lamina propria (13). The development of isolated
lymphoid follicles (ILFs), specialized intestinal structures made of mostly dendritic cells
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(DC) and B cell aggregates, is also dependent on the microbiota (14). Therefore, multiple
populations of intestinal immune cells require the microbiota for their development and their
function.
The absence of a microbiota also leads to several extra-intestinal defects, including reduced
numbers of CD4+ T cells in the spleen, fewer and smaller germinal centers within the spleen
and reduced systemic antibody levels, which suggests that the microbiota are capable of
shaping systemic immunity (15–17). Beyond development, the microbiota also influences
functional aspects of intestinal and systemic immunity, including pathogen clearance. Germ-
free mice are more susceptible to infectious agents such as Shigella flexneri, Bacillus
anthracis and Leishmania (18). Peptidoglycan from the microbiota enhances neutrophil
cytotoxicity following systemic infections by Streptococcus pneumoniae and
Staphylococcus aureus (19). During systemic challenge of mice with Listeria
monocytogenes, germ-free mice harbored an increased bacterial burden in the liver, spleen
and peritoneal cavity (20). Moreover, trafficking of T lymphocytes to the peritoneal cavity
in response to Listeria infection is impaired in germ-free mice.
The contributions of the microbiota to the development and function of the immune system
appear to be fundamental. A more robust immune system, equipped with a diverse arsenal of
cells and molecules, is better able to combat microbial pathogens and ultimately provides a
healthier residence for commensal bacteria. This view implies that host mechanisms and the
microbiota may have evolved to collaborate against infectious agents. Indeed, several
reports now show an antagonistic relationship between overt pathogens and the microbiota.
For example, Salmonella trigger intestinal inflammation, which reduces the numbers and
diversity of the microbiota, a process which promotes bacterial infection (21). Depletion of
the microbiota diminishes intestinal immune responses that help control enteric infections by
Citrobacter rodentium and Campylobacter jejuni (22). Given the role of the microbiota in
immune system function, harnessing the immunomodulatory capabilities of the microbiota
may offer novel avenues for development of anti-microbial therapies for infectious disease.
How does the Microbiota Provide Signals to Instruct Peripheral Regulatory
T cell Differentiation?
Although many cell types are influenced by the microbiota, we will focus here on the
emerging role of the microbiota on effector CD4+ T cell differentiation. After lineage
commitment in the thymus, naïve CD4+ T cells enter the periphery where they sense
environmental signals that further instruct their maturation and function. During an
infection, microbial and host signals provide cues to naïve CD4+ T cells to induce their
differentiation into various pro- and anti-inflammatory subsets. For instance, infection by
intracellular pathogens drives the development of T-helper 1 (Th1) cells, whereas
extracellular pathogens induce the differentiation of Th2 and Th17 subsets (23). These pro-
inflammatory cells coordinate many aspects of the innate and adaptive immune response to
clear microbial invaders. CD4+ T cells can also adopt an anti-inflammatory phenotype.
Regulatory T cells (Tregs) control unwanted immune system activation and dampen
inflammation after microbial infection. Expression of the Treg cell-specific transcription
factor Foxp3 (forkhead box P3) induces regulatory phenotypes and functions by CD4+ T
cells (24). Foxp3+ T cells develop in the thymus shortly after birth, and deletion or depletion
of Foxp3+ T cells leads to severe multi-organ lymphoproliferative disease and autoimmunity
(25). Besides the thymus-derived CD4+Foxp3+ T cells (‘natural’ Tregs), various subsets of
Tregs can be generated in the gut from naïve T cells (‘inducible’ Tregs), some of which
produce the anti-inflammatory cytokine interleukin-10 (26). Moreover, intestinal bacteria
may be critically involved in the differentiation of some gut Treg subsets (29–31).
Accordingly, several commensal bacteria (e.g., Bifidobacteria infantis, Faecalibacterium
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prausnitzii) have been shown to induce Foxp3+ Tregs and IL-10 production in the gut (32–
33).
Members of the genus Bacteroides are prominent in the mammalian gastrointestinal tract,
and are also potent stimulators of the mucosal immune system of mammals (34). The gut
microorganism Bacteroides fragilis has emerged as a model system for the study of
immune-bacterial symbiosis. During colonization of mice with B. fragilis, the bacterial
molecule Polysaccharide A (PSA) directs the cellular and physical development of the
immune system (16). Moreover, B. fragilis is able to prevent intestinal pathology in two
independent models of experimental colitis in a PSA-dependent manner (35). Furthermore,
in mouse models of experimental colitis, oral treatment of mice with purified PSA protects
against weight loss, decreases pro-inflammatory cytokine expression in the gut, and inhibits
lymphocyte infiltration that is associated with disease. The protective effects of PSA were
likely mediated by CD4+ T cell production of IL-10 because CD4+ T lymphocytes from
mesenteric lymph nodes of PSA treated mice produced elevated amounts of IL-10. IL-10-
deficient CD4+ T cells abolished the protective effects of PSA in both colitis models. These
studies identify PSA as a beneficial microbial molecule, which suppresses inflammation-
driven host pathology.
No consensus has been reached about whether Foxp3+ Treg cells in the intestinal tissues of
germ-free mice are defective (36–40); however, production of IL-10 is reduced within the
GALT of germ-free animals (13, 36, 41). Foxp3+ Treg cells in the colon of germ-free mice
exhibit reduced IL-10 expression, and colonization of germ-free mice with PSA-producing
bacteria (but not PSA-deficient B. fragilis) restores IL-10 expression (42). PSA increases the
Foxp3 expression by Treg cells, and colonization of germ-free animals with B. fragilis
augments the in vitro suppressive activity of Tregs in a PSA-dependent manner (42). PSA
protects and cures animals from experimental colitis by inducing Foxp3+ Treg cells and
IL-10 production. These findings imply that optimal Foxp3+ Treg cell differentiation in the
colon requires signals from the microbiota and the host genome. They also suggest specific
commensal bacteria may have evolved to promote Treg cell differentiation in the gut to
actively engender mucosal tolerance to the host. If validated in human disease, these
findings may lead to probiotic therapies for colitis based on microbial-driven Treg induction.
How does the Microbiota Instruct T-helper Cell Differentiation?
Although the microbiota has been shown to affect the Th1/Th2 balance in systemic immune
compartments (43), studies have not yet observed symbiotic microbial effects on Th1 or Th2
cells at mucosal surfaces. In contrast, Th17 cell development in the gut is specifically
impacted by commensal bacteria. Germ-free mice are deficient in the production of IL-17
from CD4+ T cells (the hallmark cytokine of Th17 cells) of the small intestinal lamina
propria (39). Only a minor defect was noted for γδ T cells, which suggests that the lack of
Th17 cells was not due to an overall deficiency in immune activation, and that specific
features of the immune response are sensitive to the microbiota. One mechanism of
intestinal Th17 cell differentiation may be production of Adenosine 5′-triphosphate (ATP) in
the lamina propria by commensal bacteria, which drives the production of Th17-inducing
cytokines by resident lamina propria cells (45). Germ-free animals display a reduction in
fecal ATP amounts and treatment of mice with a non-hydrolysable ATP analogue increased
the number of gut Th17 cells (45).
Not all bacterial species of the microbiota are similar in their ability to promote non-
pathogenic T cell responses during normal colonization of animals. Of the numerous
bacterial phylotypes that comprise the normal microbiota of mice, only segmented
filamentous bacteria (SFBs) have been shown to direct intestinal T-helper cell development.
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A role for SFBs was identified by reconstituting germ-free mice with various subsets of
bacterial consortia and measuring cytokine production in gut mucosal tissues (41). SFBs,
which are known to tightly adhere to the intestinal mucosa (and to Peyer’s patches of the
ileum), induced the development of T-helper cells in the lamina propria and in cell
aggregates of Peyer’s patches. This activity was not found in even very complex groups of
bacteria tested if they were missing SFBs. In a contemporary report, a comparison of the
microbiota of mice that contained Th17 cells with mice deficient in these cell types
identified SFBs as being sufficient to restore Th17 cells to germ-free mice and
conventionally raised mice that lack Th17 cells (46). Gene expression analysis showed that
SFBs induce a spectrum of intestinal immune responses including production of cytokines
and chemokines, antimicrobial peptides, and serum amyloid A (SAA), which was shown in
vitro to support Th17 cell differentiation. SFB colonization protected animals from intestinal
infection with Citrobacter rodentium, a bacterial pathogen of animals that causes acute
intestinal inflammation similar to enteropathogenic Escherichia coli (EPEC) in humans.
Thus, commensal SFBs induce a tonic (or controlled) inflammatory response in the gut
through Th17 cell development that does not cause pathology and is protective against
infection with pathogenic bacteria. These new studies build on research done several
decades ago that SFBs promote germinal center development, mucosal IgA responses and
recruitment of intraepithelial lymphocytes (47–49). Collectively, it appears that only a
particular subset of bacteria from the gut microbiota directly influences Th17 immune
responses.
Are Non-infectious Human Diseases Influenced by the Microbiota?
Numerous autoimmune diseases result from dysregulation of the adaptive immune system.
The incidences of autoimmune diseases such as multiple sclerosis (MS), type 1 diabetes
(T1D) and rheumatoid arthritis (RA) are rapidly increasing in Western societies, suggesting
alterations in environment factors that regulate the adaptive immune system. As appreciation
for the immunomodulatory potentials of commensal bacteria have increased, we and others
have proposed that lifestyle changes have caused a fundamental alteration in our association
with the microbial world (50–51). Altered diets, widespread antibiotic use and other societal
factors in developed countries may result in an unnatural shift in the community
composition of a ‘healthy’ microbiota, leading to altered microbial colonization known as
dysbiosis. Whether dysbiosis causes any human disease is yet unproven (insights may come
from microbiome sequencing projects); however, evidence in mice suggests dysbiosis may
affect autoimmunity by altering the balance between toleragenic and inflammatory members
of the microbiota (Fig. 2). PSA from B. fragilis, previously shown to treat experimental
colitis in the gut, is also able to prevent and cure experimental autoimmune
encephalomyelitis (EAE; an animal model for multiple sclerosis) (52). Oral treatment of
animals with PSA reduced Th17 cell development and increased Treg numbers in the central
nervous system (CNS). Furthermore, germ-free animals display reduced Th17 cell numbers
in the spleen and spinal cords, and do not develop RA or EAE (inflammation in joints and
the CNS, respectively) (53–54). The inflammatory responses in both RA and EAE are
promoted by Th17 cells and prevented by Tregs, which suggests that the effects of gut
bacteria on the adaptive immune system likely extend beyond the gastrointestinal tract to
influence autoimmune diseases that are seemingly unrelated to microbial infections.
Why only specific commensal bacteria induce Th17 cell differentiation remains unclear.
Th17 responses are critical at mucosal surfaces to control infections by extracellular
pathogens. IL-17 production recruits neutrophils to the site of infection and induces
antimicrobial peptide expression and other mediators of immunity. If there is an
evolutionary rationale for the ability of SFBs to induce Th17 cell differentiation, one
interpretation is that they mediate a state of ‘controlled inflammation’, which prepares the
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gastrointestinal tract for an invading pathogen. SFBs are not overt pathogens and colonize
animals as symbionts, and thus Th17 induction may lead to more enhanced immune
responses that protect against acute infectious agents (such as C. rodentium). Besides this
beneficial outcome, it appears that SFB colonization also leads to adverse host effects. Th1
and Th17 cells of the adaptive immune system promote autoimmunity. As a result, microbes
which stimulate T-helper cell development may (inadvertently) also increase the inherent
immune reactivity of the host, potentially leading to host-destructive pathologies mediated
by the adaptive immune system. This notion is supported by a role for SFBs in promoting
RA and EAE during induced animal models, both of which involve Th17 cell inflammation
(53–54). The enhancement of RA and EAE by SFBs establishes that the microbiota can
adversely influence autoimmune disease outside the gut. Therefore, SFBs can colonize
healthy animals without causing illness; but when the host is immunocompromised or under
inflammatory conditions, SFBs can be detrimental. We propose that certain microbes, such
as SFBs, which can peacefully co-exist with a healthy host but still retain pathogenic
potential be termed ‘pathobionts’, to distinguish them from opportunistic pathogens which
are acquired from the environment and cause acute infections (55). Pathobionts may
represent organisms on the evolutionary continuum between an acute pathogen and
commensal, whose sustained relationships with the host induces the development of
additional layers of mucosal defense while promoting the unwanted side effect of
autoimmune disease. The significance of Th17 cell-inducing organisms such as SFBs to
animal models of autoimmunity remains to be further established, as caveats exist such as
the fact that animals from colonies devoid of SFBs can develop autoimmune disease. Also,
how the microbiota may contribute to human autoimmunity needs to be determined. SFB
colonization of animals, however, does provide a model system for testing concepts linking
specific gut bacteria to non-intestinal immune disorders. The identification of bacterial
molecules required for SFBs to induce Th17 cell responses may reveal why this particular
organism is capable of promoting the development of pro-inflammatory T cells.
Furthermore, studies that delineate the gene regulatory networks induced by SFB
colonization may enhance our understanding of the evolutionary forces that resulted in Th17
lineage development.
Autoimmune diseases such as MS, T1D and RA are associated with a spectrum of genetic
polymorphisms as shown by recent genome wide association studies. Given that
concordance rates for disease among monozygotic twins averages between 20–40%,
environmental factors are crucial for the manifestations of symptoms (56). We predict that
autoimmunity can result from the combination of an altered human genome and an altered
microbiome (Fig. 2). Patients with autoimmunity likely have a genetic landscape that
predisposes them to self-reactivity, and in some cases, certain gut bacteria may promote
disease by activating the adaptive immune system. Potential future treatments for
autoimmunity may include treatment of dysbiosis, because whereas the human genome is
static and intransigent to manipulation, the microbiome is conceivably more amenable to
therapeutic alterations. Understanding the molecular mechanisms of how symbiotic
microbes affect immune reactions to self antigens may provide insight into the causes, and
potential cures, for autoimmune diseases.
Did the Microbiota Influence the Evolution of Adaptive Immunity?
The adaptive immune system distinguishes between self and foreign antigens, and mounts
an appropriate response to clear invading pathogens by recognizing non-self molecules. The
microbiota presents a challenge to the adaptive immune system, because it contains an
enormous foreign antigenic burden, which must be either ignored or tolerated to maintain
health. One hypothesis for how this occurs is ‘immunologic ignorance’, whereby spatial
separation of bacteria from the immune system or down-modulation of innate immunity
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prevents overt inflammation (57). This notion is feasible, because the innate immune system
cannot distinguish pathogens from symbionts because both share similar molecular patterns
(such as TLR ligands). Rather than ignorance, tolerance could also be induced by the
microbiota, given the capacity of gut bacteria to induce Treg lineage differentiation.
Molecules produced by our microbiome may be considered ‘self’, because inflammatory
bowel disease (IBD) is thought to, in part, involve a loss of tolerance to antigens of the
microbiota. Therefore it appears that rather than ignore them, we may tolerate the microbiota
similar to antigens encoded by our own genome. This then raises the question of whether
symbiotic bacteria evolved mechanisms to suppress unwanted inflammation toward the
microbiota by actively inducing mucosal tolerance. Several studies now suggest this to be
the case (32–33, 42). The necessity for the microbiota to induce tolerance as a requirement
for colonization, if true, provides a rationale for why symbiotic bacteria may have
influenced critical aspects of the adaptive immune system throughout mammalian evolution.
Although T cells can adopt numerous effector cell fates (such as Th1, Th2, Th3, Th9, etc),
there are common mechanistic foundations to Th17 and Treg cell development.
Differentiation of both lineages are promoted by transforming growth factor β (TGFβ);
Tregs require TGFβ (and retinoic acid), whereas TGFβ and IL-6 promote Th17 development
(23). The central transcription factors for Treg cells and Th17 cells (Foxp3 and RORγt,
respectively) are co-expressed in naïve CD4+ T cells, physically interact with each other,
and differentially respond to cytokine stimulation to help determine lineage commitment
between Foxp3+ Treg and Th17 differentiation (58). Furthermore, Th17 cells can develop
from Foxp3+ Treg cell precursors (59). As mentioned above, germ-free animals show
decreased Th17 cell development in several anatomic locations (39, 45, 53–54) and re-
colonization with a microbiota (containing SFBs) promotes Th17 cells (46, 53–54). On the
basis of this knowledge, we propose a hypothetical model for how specific commensal
bacteria network with an evolving adaptive immune system (Fig. 3). Thymically-derived
Foxp3+ Treg cells developed under the control of the evolutionary ancient molecule TGFβ.
It is tempting to speculate that commensal microbes (for example B. fragilis) may have
‘learned’ to augment this process by further promoting differentiation of existing Treg cells
into expanded subsets, such as those producing IL-10 at mucosal surfaces. This expanded
Treg cell repertoire could have provided the host with a mechanism to tolerate foreign
antigens of the microbiota. Pathobionts such as SFBs may have further modified the
development of adaptive immunity by promoting the differentiation of Th17 cells, in part
from Foxp3+ precursors. In support of this notion, IL-17 family members have only been
found in vertebrates (60). Other pro-inflammatory cytokines (IL-6, IL-21 and IL-1) along
with TGFβ are required to induce IL-17 production, perhaps suggesting Th17 cells might be
a more recent invention than Treg cells. Perhaps the evolution of specific immune responses
was not mainly driven by pathogens (as is popular assumption), but instead by organisms
that developed more sustained relationships with the host such as commensals and
pathobionts. As these new symbiotic relationships were forged through host-microbial co-
evolution, novel additions to the immune system were introduced over millennia. Although
this hypothesis requires validation, Treg and Th17 cells provide a powerful means by which
mucosal surfaces can be protected from unwanted inflammatory responses to the microbiota
(by Treg cells) while still being capable of potently responding to microbial infections (with
Th17 cells). B. fragilis and SFBs represent model organisms that have been experimentally
validated to provide these functions; other microbes may possess similar activities.
Together, the coordination of Treg and Th17 responses appears ideally suited to benefit both
the microbiota and the host, and may represent an important evolutionary partnership for
human health.
Co-opting an antigen-specific adaptive immune system by the microbiota may extend
beyond simply a host-derived process for controlling microbial infections. During co-
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habitation with the microbiota, evolution of the vertebrate genome occurred under the
influence of signals from symbiotic bacteria. In fact, the evolutionary forces that contributed
to immune system development during lifelong microbial associations may be dominant
compared to those of transient encounters by microbial pathogens (which are rare and
opportunistic). Thus, symbiotic microbes may have influenced features of adaptive immune
system evolution and function more profoundly than pathogens, possibly to protect both host
and microbiota from invading infections. As an increasing body of knowledge links the
microbiota to Treg and Th17 phenotypes that mediate autoimmunity, it is imperative to
determine how signals from the microbiota shape gene regulatory networks by CD4+ T cells
following their thymic development. If these co-evolutionary interactions are relatively
recent inventions, is autoimmunity an unwanted side effect from fine-tuning of the
peripheral adaptive immune system by the microbiota? As the influences of the microbiota
on autoimmune diseases are unraveled, it can be envisioned that harnessing the ability of the
microbiota to induce tolerance through Treg cells may provide novel treatments for
autoimmunity by correcting immunologic imbalances found in an evolving adaptive
immune system. Finally, as we harbor 10-fold more bacterial cells than human cells,
explorations into how the microbiota may have influenced the evolution of adaptive
immunity might redefine how we view our ‘microbial selves’.
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Fig. 1.
The microbiome of various anatomical location of the human body. Numerous bacterial
species colonize the mouth, upper airways, skin, vagina and intestinal tract of humans. The
phylogenic trees show the speciation of bacterial clades from common ancestors at each
anatomical site. Although the communities in different regions of the body share
similarities, they each have a unique site-specific ‘fingerprint’ made of many distinct
microbes. Each site has a very high level of diversity, as shown by the individual lines on
the dendograms. Data is from the NIH funded Human Microbiome Project, and circles
represent bacterial species whose sequences are known. NOTE TO SCIENCE EDITORS: the
figure of the body was taken from GOOGLE images and the phylogenic trees were taken
from the Human Microbiome Project. Please address any copyright issues and/or redraw
figures.
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Fig. 2.
How the microbiome and the human genome contribute to inflammatory disease. In a
simplified model, the community composition of the human microbiome helps to shape the
balance between immuneregulatory (Treg) and pro-inflammatory (Th17) T cells. The
molecules produced by a given microbiome network work with the molecules produced by
the human genome to determine this equilibrium. (A) In a healthy microbiome, there is an
optimal proportion of both pro- and anti-inflammatory organisms (represented here by SFBs
and B. fragilis), which provide signals to the developing immune system (controlled by the
host genome) that leads to a balance of Treg and Th17 cell activities. In this scenario, the
host genome can contain ‘autoimmune specific’ mutations (represented by the stars), but
disease does not develop. (B, C) The genome of patients with multiple sclerosis, type I
diabetes, rheumatoid arthritis and Crohn’s disease contain a spectrum of variants that are
linked to disease by genome wide association studies (reviewed in (61)). Environmental
influences, however, are risk factors in all of these diseases. Altered community composition
of the microbiome due to lifestyle, known as dysbiosis, may represent this disease
modifying component. An increase in pro-inflammatory microbes, for example SFBs in
animal models, may promote Th17 cell activity to increase and thus predispose genetically
susceptible people to Th17-mediated autoimmunity (B). Alternatively, a decrease or absence
in anti-inflammatory microbes, for example B. fragilis in animal models, may lead to an
under-development of Treg cell subsets (C). The imbalance between Th17 cells and Tregs
ultimately leads to autoimmunity.
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Fig. 3.
A model for the co-evolution of adaptive immunity with the microbiota. (A) The adaptive
immune system develops under the control of the vertebrate genome to produce various cell
types. The evolutionarily ancient molecule TGFβ directs the differentiation of Foxp3+ Treg
cells. Although the earliest mammals contained a gut microbiota, bacteria may or may not
have influenced features of the primordial adaptive immune system. (B) Over millennia of
co-evolution, commensal microbes (B. fragilis used as an example here) produced molecules
that networked with the primordial immune system to help expand various Treg cell subsets,
for example IL-10-producing Foxp3+ Treg cells. This process may have evolved to allow
these microorganisms to colonize the gut by inducing antigen-specific tolerance to the
microbiota. (C) Pro-inflammatory pathobionts (such as SFBs) may have induced Th17 cell
differentiation to increase mucosal defenses against enteric pathogens. (D) The modern
adaptive immune system may have arisen from 2 distinct events: Tregs and Th17 cell types
evolved independently (A to B and A to C), or through the sequential development of Th17
cells from Treg cell precursors (A to B to C to D). This may have been achieved by a
combinatorial signal of TGFβ, augmented by the addition of IL-6 to promote Th17 cell
evolution over time (inset). Together, the modulation of Tregs and Th17 cells by commensal
and pathobionts, respectively, appears to shape the immune status of the host, and thus
represents a possible risk factor for autoimmune diseases which appear to depend on
balanced Treg/Th17 proportions.
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